<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305967</url>
  </required_header>
  <id_info>
    <org_study_id>SB Injection</org_study_id>
    <nct_id>NCT01305967</nct_id>
  </id_info>
  <brief_title>Investigation of Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase â…¡a,Open Label,Multicenter Clinical Trial to Investigate Safety and Efficacy of SB Injection in Patients With Advanced and Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SBPharmaceutical IND, Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SBPharmaceutical IND, Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of SB injection in Non Small Cell Lung
      Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will receive SB injection therapy for 4 cycles (14~21 days for each
      cycle). SB injection treatment could be continue after completion of therapy cycles until 6th
      cycle. It depends on the investigator's decision and patient's will. Efficacy will be
      evaluated every two cycles.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Best Response Rate</measure>
    <time_frame>2.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine duration of response rate by measuring time to progression</measure>
    <time_frame>2.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>2.5months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evalute patient's performance by measuring the Eastern Cooperative Oncology Group scale</measure>
    <time_frame>2.5months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB injection</intervention_name>
    <description>Infusion SBinjection of 21.87ml/m^2, Intravenous route, 16times for 2.5 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18-70 years

          -  Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer

          -  Patients who had failed more than 1 cycle of standard therapy with advanced or
             metasatic stage not available to any of resectable surgery or radiotherapy.

          -  Patients with measurable lesions

          -  Eatern Cooperative Oncolgy Group status 0 to 2.

          -  Life expectancy &gt;/= 5 months

          -  Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined
             by

               1. Absolute neutrophil count &gt;/= 1.5 x 10^9/L, Platelet count &gt;/= 100 x 10^9/L

               2. Total bilirubin &lt;/= upper limit of normal

               3. Aspartate Aminotransferase and/or Alanine Aminotransferase &lt;/= 2 x upeer limit of
                  normal

               4. creatinine &lt;/= 1.5 x upeer limit of normal

          -  Patients who have signed the informed consent form.

        Exclusion Criteria:

          -  Female volunteers admitted to the study must be using a reliable means of
             contraception

          -  Received radiation therapy within 6 weeks before randomization

          -  Known brain or spinal cord metastases

          -  Have acute infection

          -  Have active infection or serious concomitant systemic disorder incompatible with the
             study

          -  Presence or history of malignancy other than Non-Small Cell Lung Cancer

          -  Have severe neurologic or psychological disorder

          -  Patients who have to receive other chemo-radiotherapy or immunotherapy

          -  Patients who have received chemotherapy within the previous 30 days

          -  Patients who are candidates for combined modality treatment.

          -  Patients who have participated in a clinical study within the previous 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-yong Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seung-beom Han, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chae-young Lee, Medical Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anyang Sam Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chae-young Lee, Medical Doctor</last_name>
    <phone>031-467-9188</phone>
    <email>joy@bovie.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>A-young Shin, Registered Nurse</last_name>
    <phone>031-467-9767</phone>
    <email>gmmi127@nate.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook University Hospital</name>
      <address>
        <city>Deagu</city>
        <state>Jung-gu</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sam Anyang Medical Center</name>
      <address>
        <city>Anyang</city>
        <state>Man-an-gu</state>
        <zip>430-733</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cae-young Lee, MD</last_name>
      <phone>031-467-9188</phone>
      <email>joy@bovie.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sbp.com/</url>
    <description>SBP</description>
  </link>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>February 27, 2011</last_update_submitted>
  <last_update_submitted_qc>February 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lee Dong-heum / executive director</name_title>
    <organization>SBPharmaceutical IND, Co., LTD</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

